What is the recommended dosing regimen for mirabegron, including initial dose, titration schedule, maximum dose, and adjustments for renal or hepatic impairment?

Mirabegron Dosing

Start mirabegron at 25 mg once daily and increase to 50 mg once daily after 4-8 weeks if needed; reduce the maximum dose to 25 mg in patients with moderate renal impairment (eGFR 15-29 mL/min/1.73 m²) or moderate hepatic impairment (Child-Pugh Class B), and avoid use entirely in severe renal impairment (eGFR <15 mL/min/1.73 m² or dialysis) or severe hepatic impairment (Child-Pugh Class C). 1

Standard Adult Dosing for Overactive Bladder

The FDA-approved dosing regimen is straightforward:

• Initial dose: 25 mg orally once daily 1
• Titration schedule: Increase to 50 mg once daily after 4-8 weeks if symptom control is inadequate 1
• Maximum dose: 50 mg once daily 1
• Administration: Swallow tablets whole with water; may take with or without food in adults 1

This dosing strategy is supported by clinical trial evidence demonstrating that both 25 mg and 50 mg doses significantly reduce incontinence episodes and micturition frequency compared to placebo, with the 50 mg dose showing numerically greater efficacy 2, 3.

Renal Impairment Adjustments

Dosing must be adjusted based on estimated glomerular filtration rate (eGFR) using the MDRD formula 1:

• eGFR 30-89 mL/min/1.73 m²: Standard dosing (start 25 mg, maximum 50 mg) 1
• eGFR 15-29 mL/min/1.73 m²: Start 25 mg once daily, maximum dose remains 25 mg (do not increase to 50 mg) 1
• eGFR <15 mL/min/1.73 m² or dialysis: Not recommended 1

The rationale for dose capping in moderate renal impairment relates to mirabegron's prolonged elimination half-life (16-18 hours versus 14-17 hours in normal renal function), which increases drug exposure 4.

Hepatic Impairment Adjustments

Adjust dosing based on Child-Pugh classification 1:

• Child-Pugh Class A (mild): Standard dosing (start 25 mg, maximum 50 mg) 1
• Child-Pugh Class B (moderate): Start 25 mg once daily, maximum dose remains 25 mg 1
• Child-Pugh Class C (severe): Not recommended 1

Pediatric Dosing (≥3 years, ≥35 kg, Neurogenic Detrusor Overactivity)

For children weighing 35 kg or more with neurogenic detrusor overactivity:

• Initial dose: 25 mg once daily 1
• Titration: Increase to 50 mg once daily after 4-8 weeks if needed 1
• Administration: Must take with food (unlike adults where food is optional) 1
• Renal/hepatic adjustments: Follow the same tables as adults 1

Missed Dose Management

If a dose is missed 1:

• Take as soon as remembered if less than 12 hours have passed since the scheduled time
• Skip the dose if more than 12 hours have passed
• Resume regular dosing schedule with the next dose

Clinical Considerations for Dose Selection

Start at 25 mg in these populations 5:

• Elderly patients with low detrusor contractility
• Patients with central nervous system lesions
• Men with benign prostatic hyperplasia
• Patients at higher risk for urinary retention

Consider 50 mg as initial therapy in patients who 5:

• Have failed antimuscarinic therapy due to cognitive side effects
• Have problematic dry mouth or constipation with antimuscarinics
• Require rapid symptom control without antimuscarinic contraindications

Combination Therapy

The AUA/SUFU guideline supports combination therapy with an antimuscarinic (specifically solifenacin 5 mg) plus mirabegron (25 or 50 mg) for patients refractory to monotherapy 6. The SYNERGY and BESIDE trials demonstrated additive efficacy with this combination, though adverse events (dry mouth, constipation, urinary retention indicators) were slightly increased 6.

Common Pitfalls

• Do not crush, chew, or divide tablets - this destroys the extended-release formulation 1
• Do not exceed 25 mg in moderate renal or hepatic impairment - higher doses increase risk of adverse cardiovascular effects 1
• Monitor blood pressure - mirabegron 50 mg causes placebo-adjusted increases of 0.4-0.6 mmHg in blood pressure and approximately 1 beat per minute in pulse rate 7
• Avoid in severe organ dysfunction - no safety data exist for severe renal or hepatic impairment 1

The 50 mg once-daily dose represents the optimal balance of efficacy and tolerability for long-term use in appropriately selected patients 8, 3, with significantly lower rates of dry mouth (2.8% at 12 months) compared to tolterodine ER 4 mg (8.6%) 3.